Trastuzumab Emtansine
ATC L01FD03 · 10 markets · 26 records
Trastuzumab Emtansine
Forms
ES 6 records · 2 strengths
AU 5 records · 5 strengths
- 160 mginjectionKADCYLA
- 100 mginjectionKADCYLA
- 171 mginjectionKADCYLA trastuzumab emtansine (rch) 100 mg powder for injection vial
- 106 mginjectionKADCYLA trastuzumab emtansine (rch) 100 mg powder for injection vial
Records without a stated strength · 1 KADCYLA
GB 4 records · 2 strengths
US 2 records · 1 strengths
- 20 mginjectionKADCYLA
CA 2 records · 2 strengths
SG 2 records · 2 strengths
- 160 mg/vialinjectionKADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
- 100 mg/vialinjectionKADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
HK 2 records · 1 strengths
Records without a stated strength · 1 KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG
TW 1 records · 1 strengths
Records without a stated strength · 1 KADCYLA、賀癌寧凍晶注射劑
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 KADCYLA
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.
A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.